Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
March 07, 2025 17:15 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating...
NanoNewron Appoints Industry Veteran Marco Taglietti, M.D., as Chief Executive Officer to Lead the Company and the Development of Their Promising Alzheimer’s Compound
March 04, 2025 15:13 ET
|
NanoNewron
Marco Taglietti, MD is appointed CEO of NanoNewron, a company developing TNF-α inhibitors for Alzheimer’s, engineered to cross the Blood-Brain Barrier
Neurology Market Research Overview 2024-2029: Growing Geriatric Population with Neurological Disorders and Increasing Global Incidence of Neurological Disorders Fueling Developments
March 03, 2025 07:21 ET
|
Research and Markets
Dublin, March 03, 2025 (GLOBE NEWSWIRE) -- The "Neurology Market: Research Overview" report has been added to ResearchAndMarkets.com's offering.The Neurology Market was valued at USD 67.3 Billion...
National Citizen Scientist Awards Honor Outstanding Clinical Trial Volunteers for Their Role in Advancing Research
February 28, 2025 09:00 ET
|
Global Alzheimer’s Platform Foundation®
Washington D.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) proudly announced the 2024 National Citizen Scientist Awards® elevated honorees at their 2025...
Global Alzheimer’s Platform Foundation Announces Strategic Collaboration with Roche for the Transformative Bio-Hermes-002 Study
February 18, 2025 09:00 ET
|
Global Alzheimer’s Platform Foundation®
Washington D.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Roche to the Bio-Hermes-002 study. This collaboration will enhance this...
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease
February 11, 2025 09:15 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering
February 04, 2025 16:31 ET
|
Annovis Bio, Inc.
MALVERN, PA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- via IBN - Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab
December 17, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s Marketplace
December 05, 2024 08:30 ET
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Dec. 05, 2024 (GLOBE NEWSWIRE) -- via IBN -- InvestorBrandNetwork, a multifaceted communications organization engaged in connecting public companies to the investment community, is...
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
November 13, 2024 09:00 ET
|
INmune Bio, Inc.
Boca Raton, Florida, Nov. 13, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that...